Work

A phase 1, first-in-human study of CTIM-76, a claudin-6 (CLDN6)-directed bispecific antibody, in patients with recurrent ovarian cancer and other advanced solid tumors.

Year: 2025

Type: article

Study design: Study Protocol

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps2685

Authors: Roisin Eilish O'Cearbhaill, Minal A. Barve, Christopher Darus, Nashat Y. Gabrail, Paul Johannet, Jade Loh, MaryBeth LeRose, Karen Andreas, Claudio Dansky Ullmann

Institutions: Memorial Sloan Kettering Cancer Center, Providence Portland Medical Center, Gabrail Cancer Center

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410809847

FWCI: 1.635

Cites:

Cited by: 3

Related to: 10